Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1997-02-13
1999-11-02
Henley, III, Raymond
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
A61K 3140
Patent
active
059771593
DESCRIPTION:
BRIEF SUMMARY
FIELD OF INVENTION
The present invention is related to the use of ACE-inhibitors for the prophylaxis and/or treatment of dyspeptic symptoms of unknown origin and to the manufacture of medicaments with effect on such dyspeptic symptoms.
BACKGROUND OF THE INVENTION
Functional disorders of the gastrointestinal tract are common and account for a very large number of medical consultations. On an annual basis approximately 30% of the western population experience such functional dyspeptic symptoms varying from mild indigestion to severe pain. The symptomatology may be due to an organic disease (for example peptic ulcer disease) or, more commonly, be without any known origin (i.e. absence of organic pathology in the upper gut as evidenced by various diagnostic procedures). In clinical routine the latter symptom-syndrome is commonly called "non-ulcer dyspepsia", "functional dyspepsia", or "non-organic dyspepsia". Current treatment of dyspepsia with unknown origin involves a variety of pharmacological principles, e.g. neutralization of gastric acidity or affecting the motility of the gut wall, some of which have doubtful efficacy and sometimes have severe side effects.
Dyspepsia due to peptic ulcer can be cured by intake of antacids and inhibitors of gastric acid secretion. Ulcer-like dyspeptic symptoms, also without mucosal pathology, usually respond to similar treatment. This sub-population of dyspeptic symptoms (acid-related dyspepsia) is thus defined by the symptom-relief in association with intake of neutralizing agents or of inhibition of gastric acid production by use of proton pump inhibitors or histamine H2-receptor antagonists. However, the former treatment is short-lasting and neutralizing drugs must be administered repeatedly during the day. The latter treatment has disadvantages of being expensive and exerting an impact on the gut physiology, as the antacid gastric conditions increase the risk for intestinal and/or systemic infections. Prokinetic drugs (such as cisapride) or anticholinergic compounds are other agents that are utilized to cure dyspeptic symptoms, usually with variable efficiency and high frequency of side effects. It follows that available drug regimens for treating dyspeptic symptoms are impaired by certain disadvantages.
The present invention relates to a new method of treating dyspepsia with unknown origin by pharmacological interference with the renin-angiotensin system (RAS).
PRIOR ART
Compounds that interfere with the renin-angiotensin system (RAS) are well known in the art and are used to treat cardiovascular diseases, particularly arterial hypertension and cardiac failure. Principally, the RAS can be interferred with by inhibition of the enzymes synthesizing angiotensins or by blocking the corresponding receptors at the effector sites. Available today are renin antagonists, inhibitors of the angiotensin converting enzyme (ACE) and angiotensin II-receptor (AII-receptor) antagonists. In addition to cardiovascular effects, some of these compounds have been claimed to exert effects on unspecified "gastrointestinal disorders".
DETAILED DESCRIPTION OF THE INVENTION
It has surprisingly been found that antihypertensive treatment by use of an angiotensin converting enzyme (ACE) inhibitor decreases the frequency and severity of dyspeptic symptoms of unknown origin (such as "non-ulcer dyspepsia," functional dyspepsia or "non-organic dyspepsia") and can act in a prophylactive manner against these symptoms. The invention describes a new method to treat dyspeptic symptoms of unknown origin by administration of an ACE-inhibitor which interferes with the synthesis of angiotensin II.
The ACE-inhibitor can be administered orally, rectally or parenterally, in neutral form or in the form of a salt. While the effects on dyspeptic symptoms have been established by the peroral route, it is considered that the effect of ACE-inhibitors is a systemic effect, which is not dependent on mode of administration.
The dose of ACE-inhibitors to be administered for the treatment of dyspeptic symptoms wi
REFERENCES:
patent: 5686451 (1997-11-01), Kristianson et al.
Indian J. Physiol Pharmacol., vol. 39, No. 3, 1995, pp. 296-298, Rao, et al., Effect of Angiotensin Converting Enzyme Inhibitor (Captopril) on Gastric Ulcer Production in Pylorus Ligated Rats.
Indian J. Physiol Pharmacol., vol. 34, No. 3, 1990, pp. 206-208, D'Souza et al., Comparison of the Effects of Captopril and Enalapril on Oxyphenbutazone and Ethanol-Induced Gastric Lesions in Rats.
Fandriks Lars
Pettersson Anders
Astra Aktiebolag
Henley III Raymond
LandOfFree
Medical use of an ace-inhibitor for treatment of dyspeptic sympt does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Medical use of an ace-inhibitor for treatment of dyspeptic sympt, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Medical use of an ace-inhibitor for treatment of dyspeptic sympt will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2136042